

Transforming Growth Factor- β 1 Induces Transdifferentiation of Myoblasts into Myofibroblasts via Up-Regulation of Sphingosine Kinase-1/S1P₃ Axis

Francesca Cencetti,^{*†} Caterina Bernacchioni,^{*†} Paola Nincheri,^{*} Chiara Donati,^{*†‡} and Paola Bruni^{*†‡}

^{*}Dipartimento di Scienze Biochimiche, Università di Firenze, 50134, Firenze, Italy; and [†]Istituto Interuniversitario di Miologia, Firenze, Italy

Submitted September 21, 2009; Revised December 15, 2009; Accepted January 12, 2010
Monitoring Editor: Kunxin Luo

The pleiotropic cytokine transforming growth factor (TGF)- β 1 is a key player in the onset of skeletal muscle fibrosis, which hampers tissue repair. However, the molecular mechanisms implicated in TGF β 1-dependent transdifferentiation of myoblasts into myofibroblasts are presently unknown. Here, we show that TGF β 1 up-regulates sphingosine kinase (SK)-1 in C2C12 myoblasts in a Smad-dependent manner, and concomitantly modifies the expression of sphingosine 1-phosphate (S1P) receptors (S1PRs). Notably, pharmacological or short interfering RNA-mediated inhibition of SK1 prevented the induction of fibrotic markers by TGF β 1. Moreover, inhibition of S1P₃, which became the highest expressed S1PR after TGF β 1 challenge, strongly attenuated the profibrotic response to TGF β 1. Furthermore, downstream of S1P₃, Rho/Rho kinase signaling was found critically implicated in the profibrotic action of TGF β 1. Importantly, we demonstrate that SK/S1P axis, known to play a key role in myogenesis via S1P₂, consequently to TGF β 1-dependent S1PR pattern remodeling, becomes responsible for transmitting a profibrotic, antidifferentiating action. This study provides new compelling information on the mechanism by which TGF β 1 gives rise to fibrosis in skeletal muscle, opening new perspectives for its pharmacological treatment. Moreover, it highlights the pleiotropic role of SK/S1P axis in skeletal myoblasts that, depending on the expressed S1PR pattern, seems capable of eliciting multiple, even contrasting biological responses.

INTRODUCTION

Repair and maintenance of skeletal muscle depends on satellite cells, tissue resident stem cells that become activated after tissue injury and rapidly generate myoblasts that proliferate, migrate at the lesion site, fuse or differentiate into new myofibers (Hawke and Garry, 2001). However, the recovery of the injured skeletal muscle often is hindered by the development of fibrosis. Skeletal muscle fibrosis is a major pathological hallmark of chronic myopathies in which myofibers are replaced by progressive deposition of extracellular matrix proteins (Huard *et al.*, 2002; Sato *et al.*, 2003). Moreover, skeletal muscle traumas provoked by repetitive muscle contractions, laceration or denervation lead also to muscular fibrosis (Best and Hunter, 2000). A major role in the onset of fibrosis is exerted by myofibroblasts that result from transdifferentiation of muscle progenitor cells during the regenerative process (Li and Huard, 2002). Among the environmental stimuli released at the injured area, transforming growth factor (TGF)- β 1 has been individuated as the major inducer of differentiation of myogenic cells into

fibrotic cells (Sato *et al.*, 2003; Li *et al.*, 2004; Gosselin *et al.*, 2004); however, the molecular mechanisms responsible for the elicited biological response have not been so far investigated.

TGF β 1, the prototypic member of a large family of multifunctional growth factors, regulates crucial events of development, disease, and repair (Rahimi and Leof, 2007). The mechanism by which TGF β -related molecules elicit their multiple biological effects is quite complex and presently not fully elucidated. The cytokine signal is transduced via a heteromeric complex of two types of transmembrane serine/threonine kinase receptors that phosphorylate receptor-activated Smad proteins. Subsequently, the translocation into the nucleus of Smad complex and its association with additional transcriptional factors determines the transcriptional regulation of target genes (Massague and Wotton, 2000; Derynck and Zhang, 2003). The long-lasting action exerted by TGF β 1 implies the triggering of a complex cascade of transcriptional events not fully characterized yet. Several recent studies have demonstrated that some of the effects elicited by TGF β 1 are transmitted by the pathway initiated by enhancement of sphingosine kinase (SK), followed by intracellular generation of the bioactive lipid sphingosine 1-phosphate (S1P) (Watterson *et al.*, 2007). Once formed, S1P can in turn act as extracellular ligand of a panel of five distinct membrane receptors or as intracellular mediator (Alvarez *et al.*, 2007). In particular, it has been shown that the SK/S1P pathway is critically implicated in the mechanism by which TGF β elicits invasive behavior of esophageal cancer cells (Miller *et al.*, 2008), antiapoptotic action in mesoangioblasts (Donati *et al.*, 2009), and profi-

This article was published online ahead of print in *MBC in Press* (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E09-09-0812>) on January 20, 2010.

[‡] These authors contributed equally to this work.

Address correspondence to: Paola Bruni (paola.bruni@unifi.it).

Abbreviations used: S1P, sphingosine 1-phosphate; SK, sphingosine kinase; SMA, smooth muscle actin; TGF, transforming growth factor.

brotic effect in various types of fibroblasts (Yamanaka *et al.*, 2004; Kono *et al.*, 2007; Gellings Lowe *et al.*, 2009). In this regard, up-regulation of SK1 has been found to be critical for the TGF β 1-induced transcriptional regulation of the tissue inhibitor of metalloproteinase-1, which inhibits degradation of extracellular matrix in fibroblasts (Yamanaka *et al.*, 2004). Moreover, recent reports have shown that SK1 plays a role in TGF β 1-dependent extracellular matrix remodeling and myofibroblast differentiation of lung fibroblasts (Kono *et al.*, 2007), and collagen production by cardiac fibroblasts (Gellings Lowe *et al.*, 2009).

Previously, we have established that SK1/S1P₂ axis is required for serum withdrawal-induced myogenic differentiation of myoblasts (Meacci *et al.*, 2008). Moreover, the prodifferentiating effect exerted by low doses of tumor necrosis factor- α in mouse myoblasts was found to rely on the triggering of SK/S1P₂ pathway (Donati *et al.*, 2007b). However, at present is not known whether SK is regulated by TGF β 1 in myoblasts and eventually participates to its biological action. The well-established profibrotic action of TGF β 1 together with the emerging role of SK/S1P axis as TGF β -regulated signaling pathway spurred us to investigate whether TGF β 1 regulates SK in myoblasts and whether it has any role in its biological response.

Data reported here show for the first time that TGF β 1 simultaneously up-regulates SK1 and profoundly modifies S1P receptor (S1PR) expression in mouse myoblasts. Importantly, S1P₃, which becomes the dominant signaling receptor upon TGF β 1 challenge, seems to be critically implicated in the transdifferentiation of myoblasts into myofibroblasts. These results represent the first experimental evidence that induction of SK1/S1P₃ axis, subsequent to S1PR expression pattern remodelling, is exploited by TGF β 1 to carry on cell transdifferentiation. Importantly, they open new perspectives for pharmacological treatment of skeletal muscle fibrosis.

MATERIALS AND METHODS

Materials

Biochemicals, TRI Reagent, cell culture reagents, DMEM, fetal calf serum (FCS), protease inhibitor cocktail, bovine serum albumin (BSA), monoclonal anti- α -smooth muscle actin (SMA) antibodies, monoclonal anti-skeletal fast myosin heavy chain (MHC) (clone MY-32), and tetramethylrhodamine B isothiocyanate (TRITC)-phalloidin conjugate were purchased from Sigma-Aldrich (St. Louis, MO). Mouse skeletal muscle C2C12 cells were obtained from the European Collection of Cell Cultures (Salisbury, UK). TGF β 1 was purchased from PeproTech (London, United Kingdom). SKI-2 [2-(*p*-hydroxyanilino)-4-(*p*-chlorophenyl)thiazole], U0126, Y27632, and D-erythro-S1P were from Calbiochem, (San Diego, CA). Short interfering RNA (siRNA) duplexes corresponding to two DNA target sequences of mouse SK1 (5'-UAGGAACUGGCCCUCUAAAdTdT3', 5'-GUGUUUAUGCAUCUGUUCUAdTdT3'); mouse S1P₂ (5'-CUCUGUACGUCCGAAUGUAdTdT3', 5'-GACUAAUCAGAUUGUAGUAdTdT3'); mouse S1P₃ (5'-CCAUAUGAUGCCAACAAGATT3', 5'-GUAAGUCAAGCUCCAGUAATT3'); mouse S1P₄ (5'-CUGCUGAACAUACACUGATT3', 5'-CUGACAUCUUUGGUUCUAATT3'); scrambled siRNA (5'-UUCUCCGAACGUGUCACGUTT3'); mouse Smad2 (5'-GAAUUGAGCCACAGAGUAAAdTdT3', 5'-UUAUCUCUGGGCUCAAUUCdTdT3'); mouse Smad3 (5'-CAGUUCUACCUCCAGUGUAdTdT3', 5'-AACACUGGAGGUAGAACUGdTdT3'); and mouse Smad4 (5'-CGAUUCAAACCAUCCAAAdTdT3', 5'-UGUUGGAUGGUUUGA-AUCGdTdT3') were from Sigma-Prologo (The Woodlands, TX). Semi-quantitative polymerase chain reaction (PCR) primers for SK1 (forward, 5'-CTTCTGGGCTGCGGCTCTATTCTG3'; reverse, 5'-GGAAAGCAACCACGGGCA-CA3') (502 base pairs) and SK2 (forward, 5'-TTGCCCTCACCTCAACA-CAAG3'; reverse, 5'-CCTCGTAAAGCAGCCCTCTCCA3') (504 base pairs) were obtained from Sigma-Prologo. Oligofectamine Reagent and Lipofectamine RNAiMAX were purchased from Invitrogen (Carlsbad, CA). Enhanced chemiluminescence (ECL) reagents and [γ -³²P]ATP (3000 Ci/mmol) were obtained from GE Healthcare Europe (Milan, Italy). [³-³H]Sphingosine, D-erythro (19.8 Ci/mmol), was from PerkinElmer Life and Analytical Sciences (Boston, MA). Secondary antibodies conjugated to horseradish peroxidase, monoclonal anti-RhoA, polyclonal anti-laminin, and polyclonal anti-Smad2/3

antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-transgelin antibodies were from Everest Biotech (Upper Heyford, Oxfordshire, United Kingdom). Monoclonal antibodies against β -actin were from Cytoskeleton (Denver, CO). Monoclonal anti-caveolin-3 and anti-hemoagglutinin (HA) antibodies were from BD Biosciences Transduction Laboratories (Lexington, KY). Polyclonal antibodies anti-Smad4 were purchased from Cell Signaling Technology (Danvers, MA). Fluorescein-conjugated horse anti-mouse secondary antibodies were obtained from Vector Laboratories (Burlingame, CA). The specific S1P_{1/3} antagonist VPC23019 and the selective S1P₁ antagonist W146 were from Avanti Polar Lipids (Alabaster, AL). All reagents and probes required to perform real-time PCR were from Applied Biosystems (Foster City, CA). pcDNA3-S1P₃ vector was a kind gift of Prof. Y. Igarashi (Hokkaido University, Sapporo, Japan).

Cell Culture

Murine C2C12 myoblasts were routinely grown in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μ g/ml streptomycin at 37°C in 5% CO₂. For myofibroblast transdifferentiation and myogenic differentiation experiments, cells were seeded in p35 or in p60 plates and when 90% confluent they were shifted to DMEM without serum containing 1 mg/ml BSA.

Sphingosine Kinase Activity Assay

SK activity was measured as described in Olivera *et al.* (1994) with few modifications, as described previously (Donati *et al.*, 2007b). Specific activity of SK was expressed as picomoles of S1P formed per minute per milligram of protein.

Western Blot Analysis

Cell lysates, cytosolic and membrane fractions, were prepared from confluent serum-starved C2C12 myoblasts as described previously (Meacci *et al.*, 2000) and then subjected to SDS-polyacrylamide gel electrophoresis and Western analysis (Donati *et al.*, 2005). Specific anti-SK1 polyclonal antibodies (directed against the 16 carboxy-terminal amino acids of the mouse SK1, kindly provided by Dr. Y. Banno, Gifu University School of Medicine, Gifu, Japan; Murate *et al.*, 2001) were used to immunodetect endogenous SK1. Rabbit polyclonal antibodies generated against SK2 (Igarashi *et al.*, 2003) were a kind gift of Dr. S. Nakamura (Department of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Japan). The expression of fibrosis markers and myogenic differentiation markers was evaluated on total cell lysates (20 μ g) after 24 and 48 h agonist challenge, respectively. Equally loaded protein was checked by expression of the nonmuscle-specific β isoform of actin. The evaluation of RhoA subcellular localization was performed by Western blotting analysis of membrane and cytosolic fractions (10 μ g) with a specific monoclonal anti-RhoA antibody.

Reverse Transcription-Polymerase Chain Reaction

Total RNA (2 μ g), extracted with TRI Reagent from C2C12 myoblasts was reverse transcribed using SuperScript II reverse transcriptase (Invitrogen) and subjected to PCR using S1P₁ (1090 base pairs), S1P₂ (336 base pairs), S1P₃ (225 base pairs), S1P₄ (324 base pairs), and β -actin (250 base pairs) PCR primers as described previously (Donati *et al.*, 2007a). β -Actin was used as an internal reference control to normalize relative levels of gene expression.

Quantitative Real-Time Reverse Transcription (RT)-PCR

The quantification of S1PR mRNA was performed by Real-Time PCR employing TaqMan Gene Expression Assays. Each measurement was carried out in triplicate, using the automated ABI Prism 7700 Sequence Detector System (Applied Biosystems, Foster City, CA), as described previously (Donati *et al.*, 2007a), by simultaneous amplification of the target sequence (S1P₁ Mm00514644_m1, S1P₂ Mm01177794_m1, S1P₃ Mm00515669_m1, and S1P₄ Mm00468695_s1; Applied Biosystems) together with the housekeeping gene 18S rRNA. Results were analyzed by ABI Prism Sequence Detection System software, version 1.7 (Applied Biosystems). The 2^{- $\Delta\Delta$ C_T} method was applied as a comparative method of quantification (Livak and Schmittgen, 2001), and data were normalized to ribosomal 18S RNA expression.

Lipid Analysis

Cell sphingolipids were labeled with [³-³H]sphingosine (0.1 μ Ci/ml for 48 h at 37°C), extracted, and separated on high performance-thin layer chromatography (HPTLC) essentially as described in Kihara *et al.*, (2003). Radioactive lipids were identified by comigration with standard lipids and quantified by a Beta-Imager 2000 instrument (Biospace, Paris, France), with an acquisition time of 48 h, essentially as described in Prinetti *et al.* (2000). The radioactivity associated with individual lipids was determined with the specific β -Vision software (Biospace).

Immunostaining and Fluorescence Microscopy

C2C12 cells were seeded on microscope slides, precoated with 2% gelatin, and then treated or not with 10 μ M SKI-2, 60 min before 5 ng/ml TGF β 1 treat-

ment. After 24 h cells were fixed in 2% paraformaldehyde in PBS for 20 min and permeabilized in 0.1% Triton X-100-PBS for 30 min. Cells were then blocked in 3% BSA for 1 h and incubated with anti- α -SMA antibody for 2 h and fluorescein-conjugated anti-mouse secondary antibody for 1 h. To stain F-actin filaments, the specimen was incubated with TRITC-phalloidin for 40 min. Images were obtained using an SP5 laser scanning confocal microscope (Leica, Wetzlar, Germany) with a 63 \times objective.

Cell Transfection

Cells grown into six-well dishes (60,000 cells/well), were transfected with siRNA duplexes using Oligofectamine Reagent transfection system, as described previously (Donati *et al.*, 2007b). In some experiments, cells were transfected using Lipofectamine RNAiMAX, according to manufacturer's instructions. In brief, Lipofectamine RNAiMAX was incubated with siRNA in DMEM without serum and antibiotics at room temperature for 20 min, and afterward the lipid/RNA complexes were added with gentle agitation to C2C12 cells to a final concentration of 50 nM in serum containing DMEM. After 24 h, cells were shifted to DMEM without serum containing 1 mg/ml BSA and then used for the experiments within 48 h from the beginning of transfection. The specific gene knockdown was evaluated by Western blot analysis or alternatively by real-time RT-PCR.

For S1P₃ overexpression, C2C12 cells were transiently transfected with pcDNA3-S1P₃ vector using Lipofectamine 2000 reagent (1 mg/ml), as described previously (Meacci *et al.*, 2003). Ectopic S1P₃ expression levels were evaluated by Western blot analysis using specific monoclonal anti-HA antibodies.

Statistical Analysis

Statistical analysis was performed using Student's *t* test. Graphical representations were performed using Excel software (Microsoft, Redmond, WA) and Prism 4.0 (GraphPad Software, San Diego, CA). Densitometric analysis of the Western blot bands was performed using imaging and analysis software Quantity One (Bio-Rad Laboratories, Hercules, CA). Asterisks indicate statistical significance (**p* < 0.05 and ***p* < 0.001).

RESULTS

TGFβ1 Regulates SK1 and Sphingolipid Metabolite Levels in C2C12 Myoblasts

The SK/S1P pathway is important in the regulation of cell fate of multiple cell types and has been already found im-




Figure 1. TGFβ1 affects SK activity and induces SK1 expression. Confluent C2C12 myoblasts were incubated with DMEM containing 1 mg/ml BSA for the indicated time intervals in the presence of 5 ng/ml TGFβ1. (A) Aliquots of cell extracts (50 μg) were used to determine SK activity. Data represent the mean ± SEM of three independent experiments each performed at least in duplicate. The effect of TGFβ1 was statistically significant by Student's *t* test (**p* < 0.05, ***p* < 0.001). (B) Top, aliquots of total cell lysates (20 μg) were used to perform Western analysis, using specific anti-SK1 and anti-SK2 antibodies. A representative blot is shown. Bottom, densitometric analysis of at least three independent experiments. Data are the mean ± SEM and are reported as protein expression normalized to β-actin, -fold change over control. (C) Two micrograms of total RNA was subjected to semiquantitative RT-PCR analysis, using specific primers for SK1, SK2, and β-actin. (D) Left, Western analysis of SK1 was performed in membrane and cytosolic fractions prepared from myoblasts treated (+) or not (-) with 5 ng/ml TGFβ1 for the indicated time intervals. A blot representative of three independent experiments with analogous results is shown. Right, densitometric analysis of three independent experiments. Data reported are the mean ± SEM of membrane:cytosol ratio to respective control set as 1.

plicated in myogenic differentiation of mouse myoblasts (Donati *et al.*, 2005; Meacci *et al.*, 2008); however, its involvement in TGF β 1 action in these cells has not been so far investigated. To explore this issue, at first we examined whether the cytokine was capable of regulating SK activity in C2C12 cells. Experimental data illustrated in Figure 1A show that cell treatment with 5 ng/ml TGF β 1 exerted a biphasic effect on SK activity. The enzymatic activity was moderately reduced at early time points (1 min–4 h range), whereas it was significantly enhanced at 18 h and still clearly appreciable at 48 h. These data are in agreement with a previous report in which the cytokine was found to reduce fibroblast SK activity and S1P cellular content within the first hour of incubation, whereas it enhanced SK activity at more prolonged times of incubation (Yamanaka *et al.*, 2004). Given that the time course of TGF β 1-dependent increase of SK activity was compatible with transcriptional regulation of SK1 or SK2, to verify this possibility Western analysis of both proteins was performed. As shown in Figure 1B, TGF β 1 treatment for 24–72 h resulted in a sustained marked increase of SK1 protein content. Instead, SK2 protein content, which was time-dependently increased by serum starvation, was not changed by the cytokine possibly due to its proapoptotic role (Igarashi *et al.*, 2003).

In agreement with the augmented protein content, SK1 mRNA levels, measured by semiquantitative PCR assay, were enhanced already at 4 h after TGF β 1 challenge, and the stimulatory effect of the cytokine was maintained at 18 h (Figure 1C). Figure 1C also shows that mRNA content of SK2 was unaffected. Given that stimulation of SK activity by multiple agonists resides on enzyme translocation to membrane, eventual TGF β 1-induced intracellular redistribution of SK1 also was explored. Western analysis of SK1 performed in cytosolic and membrane fractions of myoblasts incubated with 5 ng/ml TGF β 1 for various time intervals revealed that the cytokine increased at similar extent SK1 protein content of cytosolic and membrane fractions (Figure 1D), thus not specifically affecting an intracellular pool of SK1. These results demonstrate that the sustained increase of SK activity elicited by TGF β 1 is exclusively attributable to the up-regulation of SK1 expression.

To further examine the effect of TGF β 1 on sphingolipid metabolism, myoblasts, previously steady-state metabolically labeled with [3 H]sphingosine, were administered with the cytokine (5 ng/ml) for various time intervals and then subjected to lipid extraction and HPTLC separation followed by digital autoradiography to quantify the various labeled sphingolipid metabolites. Data presented in Figure 2 show that [3 H]ceramide levels were enhanced by TGF β 1 within 6 h, whereas at more prolonged times (18–24 h) they were significantly reduced. In parallel, [3 H]sphingosine levels were not appreciably modified throughout the incubation. Interestingly, treatment with TGF β 1 at 18 and 24 h raised [3 H]S1P levels by ~60%. Thus, consistently with the complex regulation of SK activity, TGF β 1 elicited changes of cellular bioactive sphingolipid metabolite levels.

Involvement of SK1 in the Profibrotic Effect of TGF β 1

To assess the ability of TGF β 1 to promote the transdifferentiation of myoblasts into myofibroblasts, the expression of fibrosis marker proteins such as α -SMA, laminin, and transgelin in C2C12 myoblasts was evaluated. Western analysis data presented in Figure 3A show that the expression of α -SMA and laminin in untreated cells underwent to a time-dependent increase, in agreement with their transient expression in skeletal myoblasts during differentiation (Olwin and Hall, 1985; Woodcock-Mitchell *et al.*, 1988); moreover,




Figure 2. TGF β 1 affects sphingolipid metabolite levels in C2C12 myoblasts. C2C12 myoblasts were labeled for 48 h with [3 - 3 H]sphingosine. Cellular lipids were extracted, separated, and analyzed as described in *Materials and Methods* section. Data represent the mean \pm SEM of three independent experiments.

the expression levels of all the chosen markers were appreciably enhanced by 5 ng/ml TGF β 1 at all the examined time intervals. In particular, TGF β 1 exerted a remarkable effect on transgelin whose levels were barely detectable in controls, whereas they were highly augmented in the cytokine-treated myoblasts. These data were in full agreement with a previous report (Li *et al.*, 2004), in which the profibrotic action of TGF β 1 in C2C12 cells was described for the first time.

Next, the potential role of TGF β 1-dependent up-regulation of SK1 in the profibrotic action of the cytokine was examined. For this purpose, C2C12 myoblasts were treated with SKI-2, a specific pharmacological inhibitor of SK, already successfully used to block the enzymatic activity in these cells (Donati *et al.*, 2007b). As shown in Figure 3B, enhanced expression of α -SMA, laminin, and transgelin induced by 24-h treatment with TGF β 1 was completely reversed by preincubation with 10 μ M SKI-2. Confocal immu-




Figure 3. SK1 is involved in TGFβ1-dependent transdifferentiation of C2C12 myoblasts. (A) Left, C2C12 myoblasts were incubated in the absence (-) or in the presence (+) of 5 ng/ml TGFβ1 for the indicated time intervals. The content of laminin, α-SMA and transgelin (Tagln) was analyzed by Western blotting in cell lysates, using specific primary antibodies. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (B) Left, C2C12 myoblasts were incubated in the presence of 10 μM SKI-2 60 min before 5 ng/ml TGFβ1 challenge for 24 h. Fibrosis marker proteins were detected as described in A. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (C) C2C12 cells were seeded on microscope slides and treated as described in B. Images were obtained using a specific mouse anti-α-SMA antibody immunorevealed by a fluorescein-conjugated secondary antibody and TRITC-phalloidin staining of F-actin filaments (images are representative of three separate experiments). (D) Left, C2C12 myoblasts, transfected with scrambled (SCR) or SK1 siRNA, incubated in the absence (-) or in the presence (+) of 5 ng/ml TGFβ1 for the last 24 h of transfection, were checked for expression of SK1 or SK2 by Western blot analysis. Densitometric analysis is showed in the right panel. (E) Left, fibrosis marker proteins were detected as described in A in lysates (20 μg) of C2C12 myoblasts transfected as described in D. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B.

nonfluorescent analysis revealed the marked enhanced expression of α-SMA in C2C12 cells treated with 5 ng/ml TGFβ1 for 24 h, which resulted mainly localized with F-actin filaments (Figure 3C). In agreement, SKI-2 treatment (10

μM) completely prevented the cytokine-induced expression of α-SMA. To further assess the involvement of SK1 in the biological response evoked by TGFβ1 in C2C12 myoblasts, SK1 was knocked down by employing siRNA technology. In




Figure 4. S1P does not induce transdifferentiation of C2C12 myoblasts. C2C12 myoblasts were incubated in the absence (–) or in the presence (+) of 1 μ M S1P for the indicated time intervals. Top, the content of laminin, α -SMA, and transgelin (Tagln) was analyzed by Western blotting in cell lysates, using specific primary antibodies. Bottom, densitometric analysis is reported as described in the legend to Figure 1B.

accordance with previous reports (Donati *et al.*, 2007b; Meacci *et al.*, 2008), specific siRNA treatment efficaciously reduced basal expression levels of SK1 (Figure 3D); moreover, it fully inhibited the TGF β 1-induced SK1 up-regulation, without affecting SK2 protein content. In agreement, the TGF β 1-dependent expression increase of laminin and α -SMA was totally abrogated when SK1 was down-regulated by RNA interference, whereas transgelin content was robustly decreased (Figure 3E), further supporting the key role of SK1 in the transdifferentiation of myoblasts into myofibroblasts brought about by TGF β 1.

Because S1P acts as profibrotic mediator in various cell types, such as cultured fibroblasts and retinal pigmented epithelial cells (Urata *et al.*, 2005; Keller *et al.*, 2007; Swaney *et al.*, 2008), the effect of exogenous S1P on fibrosis marker proteins was then investigated. Treatment of myoblasts with 1 μ M S1P for various time intervals did not influence the expression of α -SMA, laminin, or transgelin (Figure 4). Analogous results were obtained employing S1P in the concentration range 1–100 nM (data not shown). Thus, TGF β 1-directed transdifferentiation of myoblasts into myofibroblasts required up-regulation of SK1 but was not mimicked by the addition with exogenous S1P, suggesting that the implicated mechanism could rely on additional molecular effects exerted by TGF β 1 on SK/S1P signaling pathway.

Profibrotic Effect of TGF β 1 Is Dependent on S1PR Expression Change

To gain further insight into the mechanism by which TGF β 1 can exploit SK/S1P axis to exert its profibrotic effect in myoblasts, we examined whether cell treatment with the cytokine affected S1PR expression pattern. Notably, semi-quantitative PCR analysis depicted in Figure 5A shows that

incubation of myoblasts for 6 or 18 h in the presence of 5 ng/ml TGF β 1, apparently reduced the band corresponding to S1P₁; increased that of S1P₃; and rendered clearly detectable a band of 324 base pairs, corresponding to S1P₄. More importantly, quantitative analysis of S1PR expression performed by real-time PCR confirmed that TGF β 1 strongly modified S1PR mRNA expression levels. In particular, it markedly reduced S1P₁ and at a lesser extent S1P₂ at 6 and 18 h of incubation, whereas it highly increased S1P₃ at both time intervals and very potently up-regulated S1P₄ mRNA levels at 18 h (Figure 5B). As a consequence, when the expression of each S1PR was referred to that of S1P₁ to calculate the ranking order, the obtained profile in untreated myoblasts was S1P₁ > S1P₃ > S1P₂ >> S1P₄, whereas it became S1P₃ > S1P₁ > S1P₄ > S1P₂ in TGF β 1-treated cells at 6 h and S1P₃ > S1P₁ > S1P₂ > S1P₄ at 18 h (Figure 5C).

Because the profound alteration of S1PR pattern provoked by TGF β 1 could be implicated in the cross-talk between the cytokine and the S1P signaling pathway, next we examined whether the profibrotic action exerted by TGF β 1 was S1PR-mediated. For this purpose, the expression of fibrosis marker proteins was evaluated in C2C12 cells challenged with TGF β 1 in the presence or absence of 1 μ M VPC23019, selective S1P₁/S1P₃ antagonist or 10 μ M W146, selective antagonist of S1P₁. Results illustrated in Figure 6, A and B, show that the increased content of α -SMA, laminin or transgelin after TGF β 1 treatment was abrogated when S1P₁ and S1P₃ were blocked but was not affected by inhibition of S1P₁, suggesting a role of S1P₃ but not S1P₁ in TGF β 1-induced response. To further support this hypothesis, individual S1PRs were knocked down by specific siRNA. Notably, as shown in Figure 6C, siRNA directed against S1P₃, which significantly reduced the receptor expression, strongly attenuated the enhancement of laminin and transgelin levels elicited by TGF β 1 and abrogated the increase of α -SMA. Conversely, the down-regulation of S1P₂ or S1P₄ by specific siRNA did not alter the profibrotic effect of the cytokine (Figure 6, D and E). Altogether, these data support the view that transactivation of S1P₃ by TGF β 1 is critical for the induction of myofibroblastic phenotype.

To confirm the importance of S1P₃ in TGF β 1-induced myofibroblast transdifferentiation, we studied whether exogenous S1P rescued the effect of TGF β 1 in myoblasts where the production of endogenous S1P was blocked. As it can be observed from Figure 7, A and B, in cells in which SK was inhibited by 10 μ M SKI-2 administration or SK1 was specifically silenced prior cell challenge with 5 ng/ml TGF β 1, treatment with 1 μ M S1P 6 h after the addition of the cytokine partially restored the stimulatory effect of TGF β 1 on transgelin expression. Importantly, S1P could not rescue the up-regulation of transgelin brought about by TGF β 1 in cells where SK was pharmacologically inhibited and S1P₃ specifically silenced by siRNA administration (Figure 7C). Moreover, in contrast to what observed in native cells (Figure 4), S1P challenge of S1P₃-overexpressing myoblasts provoked an appreciable increase of transgelin expression, whereas the profibrotic response elicited by TGF β 1 was significantly enhanced (Figure 7D). These data provide further experimental evidence that up-regulation of S1P₃ by TGF β 1 is required to readdress S1P signaling toward the onset of myofibroblastic phenotype.

Up-Regulation of SK1/S1P₃ Induced by TGF β 1 Is Smad Dependent

Given that Smad proteins transmit most of the transcriptional effect exerted by TGF β 1, subsequently their implication in the up-regulation of SK1 and/or S1P₃ by TGF β 1 was




Figure 5. TGFβ1 modulates the expression of S1PRs. (A) Two micrograms of total RNA extracted from C2C12 myoblasts stimulated (+) or not (-) with 5 ng/ml TGFβ1 for the indicated time intervals was subjected to semiquantitative RT-PCR analysis, using specific primers for S1P₁, S1P₂, S1P₃, S1P₄, and β-actin. (B) Quantitative mRNA analysis was performed by real-time PCR in total RNA extracted from C2C12 myoblasts stimulated (+) or not (-) with 5 ng/ml TGFβ1 for the indicated time intervals. S1PR mRNA quantitation was based on the $2^{-\Delta\Delta C_T}$ method, using individual S1PR subtype of the unchallenged specimen as calibrator. (C) Quantitative mRNA analysis was performed as described in B. Results are expressed as -fold changes according to the $2^{-\Delta\Delta C_T}$ method, using S1P₁ as calibrator. Data are the mean \pm SD of one representative experiment performed in triplicate and repeated three times with analogous results.

examined. For this purpose, myoblasts transfected with specific siRNAs, capable of significantly attenuating the expression of Smad2, Smad3, or Smad4 (Figure 8A), were tested for the responsiveness to TGFβ1 in regard to up-regulation of SK1/S1P₃ axis. As shown in Figure 8B, silencing of Smad2, Smad3, or Smad4 blunted the TGFβ1-dependent increase of SK1 protein content at 24 h; moreover, it also abolished the enhancement of S1P₃ mRNA content elicited at the same time of incubation (Figure 8C). In agreement with these results, silencing of Smad2 or Smad3 strongly attenuated the expression of transgelin, which was fully abolished by Smad4 knockdown (Figure 8B).

Profibrotic Response Elicited by TGFβ1 Is Downstream of Rho/Rho Kinase Pathway

Next, to investigate the signaling pathways downstream of SK1/S1P₃ axis implicated in the TGFβ1-directed myoblast transdifferentiation into myofibroblasts, cells were incu-

bated with compounds such as U0126 (10 μM) or Y27632 (25 μM), which specifically inhibit extracellular signal-regulated kinase (ERK)1/2 and Rho kinase pathway, respectively. As shown in Figure 9A, prevention of ERK1/2 or Rho kinase activation did not impair TGFβ1-induced SK1, but Rho kinase inhibition strongly reduced the positive effect of the cytokine on transgelin protein content. Thus, these results suggest that Rho kinase is downstream of SK1 induction and upstream of fibrosis marker expression triggered by TGFβ1.

Because Rho kinase activity relies on stimulation by RhoA, it was then examined the effect of TGFβ1 on RhoA intracellular distribution, a validated procedure to assess the entity of active GTP-bound RhoA in C2C12 myoblasts (Macci *et al.*, 2000). As illustrated in Figure 9B, 5 ng/ml TGFβ1 provoked an early increase of membrane-bound RhoA, evident already at 1 h of incubation, and a more delayed effect clearly appreciable at 8 h, still detectable at 16 h. Interestingly, preincubation with 10 μM SKI-2 did not affect the




Figure 6. Role of S1PRs in TGFβ1-induced transdifferentiation of C2C12 myoblasts. (A) Left, confluent serum-starved C2C12 myoblasts were treated with or without 1 μM VPC23019 30 min before 5 ng/ml TGFβ1 challenge for 24 h. The content of laminin, α-SMA, and transgelin (Tagln) was analyzed by Western blotting of whole cell lysates (20 μg). Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (B) Left, confluent serum-starved C2C12 myoblasts were treated with or without 10 μM W146, 30 min before 5 ng/ml TGFβ1 challenge for 24 h. Fibrosis marker proteins were detected as described in A. Right, data are reported as described in the legend to Figure 1B. (C) C2C12 myoblasts, transfected with scrambled (SCR) or SIP₃ siRNA, incubated in the absence (–) or in the presence (+) of 5 ng/ml TGFβ1 for the last 24 h of transfection, were checked for down-regulation by real-time PCR (left). Middle, fibrosis marker proteins were analyzed as described in A. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. Myoblasts transfected with SCR or SIP₂ siRNA (D) and with SCR or SIP₄ siRNA (E) were treated and used as described in C.

early RhoA activation but abrogated the delayed activation, indicating that SK activation was upstream of this TGFβ1-driven molecular event. Moreover, the enhancement of membrane-bound RhoA induced by 8-h TGFβ1 treatment was prevented by previous cell incubation with 1 μM VPC23019 (Figure 9C). These findings were corroborated by

results obtained in myoblasts where SK1 or SIP₃ were knocked down by transfection with specific siRNA. Both experimental conditions prevented TGFβ1-dependent RhoA association to membrane at 8 h of incubation (Figure 9D). These data strongly support the view that up-regulation of SK1 as well as SIP₃ are critically required for RhoA activa-




Figure 7. Dominant S1P₃ signaling is required for the induction of profibrotic response by S1P. (A) Left, confluent serum-starved C2C12 myoblasts were pretreated or not with 10 μM SKI-2 for 60 min and then incubated in the presence (+) or absence (-) of 5 ng/ml TGFβ1, 6 h before the challenge with 1 μM S1P for 24 h. Transgelin (Tagln) was detected in aliquots (20 μg) of total cell lysates by Western blot analysis. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (B) C2C12 myoblasts, transfected with scrambled (SCR) or SK1 siRNA, were incubated for 24 h in the presence (+) or absence (-) of 5 ng/ml TGFβ1, 6 h before 1 μM S1P challenge. Tagln was detected as described in A. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (C) Left, C2C12 myoblasts, transfected with SCR or S1P₃ siRNA, were treated with 10 μM SKI-2 for 60 min and then incubated in the presence (+) or absence (-) of 5 ng/ml TGFβ1, 6 h before 1 μM S1P challenge. Tagln was detected as described in A. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B. (D) Left, C2C12 cells were transiently transfected with pcDNA3-S1P₃ or empty vector. Cells were treated with 1 μM S1P or 5 ng/ml TGFβ1 for 24 h and cell lysates used to detect Tagln as described in A. Inset, S1P₃ expression levels was evaluated in transfected C2C12 myoblasts by Western blot analysis using specific monoclonal anti-HA antibodies. Right, densitometric analysis. Data are reported as described in the legend to Figure 1B.

tion by TGFβ1, necessary in turn for the induction of myofibroblastic phenotype via Rho kinase stimulation.

SK1/S1P₃ Signaling Pathway Is Implicated in the Antimyogetic Action of TGFβ1

The antidifferentiating property of TGFβ1 is well established (Olson *et al.*, 1986; Leask and Abraham, 2004). In agreement, treatment of myoblasts with the cytokine (5 ng/ml) caused a strong reduction of expression of known myogenic markers such as myosin heavy chain (MHC), and caveolin-3 at all the chosen times of incubation (Figure 10). Figure 10 also

shows that the inhibition of SK signaling pathway by pre-incubation with 10 μM SKI-2 attenuated the inhibitory effect of TGFβ1 on myogenesis at 48 h of incubation. In accordance, a similar reduction of the antimyogetic effect of TGFβ1 was detected in myoblasts where SK1 was specifically down-regulated by siRNA treatment. Moreover, Figure 10 shows that the inhibitory effect of TGFβ1 on myogenesis was likewise diminished in cells where S1P₃ was knocked down. These results support the view that trans-activation of S1P₃ by TGFβ1 plays also a role in its antimyogetic action.




Figure 8. Role of Smad proteins in TGFβ1-dependent SK1 and S1P₃ up-regulation and in TGFβ1-induced transdifferentiation of C2C12 myoblasts. C2C12 myoblasts were transfected with Smad2 or Smad3 or Smad4 siRNA, using scrambled (SCR) siRNA as a control. (A) Top, C2C12 myoblasts were checked for expression of Smad2, Smad3, or Smad4 by Western blot analysis, using specific anti-Smad2/3 or anti-Smad4 antibodies. Densitometric analysis is shown in the bottom panels. Data are reported as described in the legend to Figure 1B. (B) Left, C2C12 myoblasts, transfected with SCR, Smad2, Smad3, or Smad4 siRNA, were incubated in the presence (+) or absence (-) of 5 ng/ml TGFβ1 for 24 h. Total cell lysates (20 μg) were subjected to Western blot analysis to detect SK1 and Transgelin (Tagln) expression. Right, densitometric analysis is reported as described in the legend to Figure 1B. (C) Quantitative analysis of S1P₃ mRNA was performed by real-time PCR in total RNA extracted from C2C12 myoblasts transfected with SCR, Smad2, Smad3, or Smad4 siRNA, stimulated (+) or not (-) with 5 ng/ml TGFβ1 for 24 h. Results are expressed as -fold changes according to the 2^{-ΔΔC_T} method, using S1P₃ subtype of the unchallenged specimen as calibrator. Data are the mean ± SD of one representative experiment performed in triplicate and repeated three times with analogous results.

DISCUSSION

In this study, we describe a novel signaling pathway triggered by TGFβ1 in C2C12 myoblasts via Smad-dependent up-regulation of SK1 and S1P₃ that is critically implicated in the transdifferentiation of myoblasts into myofibroblasts through Rho/Rho kinase signaling pathway.

Recent studies have highlighted a pivotal role of TGFβ1-directed SK1 up-regulation in mediating the profibrotic action in different types of fibroblasts (Yamanaka *et al.*, 2004; Kono *et al.*, 2007; Gellings Lowe *et al.*, 2009), in full accordance with the profibrotic effect exerted by S1P in various cellular contexts, including human lung and dermal fibroblasts and retinal pigmented epithelial cells (Urata *et al.*, 2005; Keller *et al.*, 2007; Swaney *et al.*, 2008). This study for the first time demonstrates that the TGFβ1-directed transcriptional regulation of SK1 and S1P₃, upstream of the up-regulation of myofibroblast marker proteins is a Smad-mediated event, where the role of Smad2, Smad3, and Smad4 seems to be critical.

Previously, we demonstrated that in myoblasts SK/S1P axis, via S1P₂ engagement, is physiologically required for the achievement of myogenic differentiation of C2C12 myo-

blasts triggered in vitro by serum withdrawal (Meacci *et al.*, 2008) or by challenge with low doses of tumor necrosis factor-α (Donati *et al.*, 2007b). In agreement, exogenous S1P was recognized previously to exert promyogenic activity in C2C12 cells, via engagement of S1P₂ (Donati *et al.*, 2005). The present finding that S1P does not influence the expression of fibrosis marker proteins in mouse myoblasts is consistent with the past results and with the notion that skeletal muscle fibrosis is associated with impairment of skeletal muscle differentiation (Best and Hunter, 2000; Sato *et al.*, 2003). Nonetheless, herein SK1 up-regulation was found to be critical for transmitting the profibrotic effect of TGFβ1 in myoblasts. Strikingly, the different biological outcome mediated by SK1/S1P axis after TGFβ1 challenge seems to depend on the effect exerted by the cytokine on S1PR expression pattern. Thus, the combined action on S1PR expression remodelling and SK1 up-regulation convey the TGFβ1-directed S1P inside-out signaling to act primarily via S1P₃, which becomes the prevailing expressed receptor, rather than S1P₂. Interestingly, the stimulation of the SK/S1P₃ axis by TGFβ1 was also implicated in its antidifferentiating activity, supporting the view that in these cells S1P-dependent pathways




Figure 9. TGFβ1-dependent transdifferentiation of C2C12 myoblasts is dependent on RhoA/Rho kinase activation, downstream of SK1 and S1P₃. (A) Left, C2C12 myoblasts were treated with or without 10 μM U0126 or 25 μM Y27632, 30 min before 5 ng/ml TGFβ1 challenge for 24 h. The content of SK1 and transgelin (Tagln) was analyzed by Western analysis of whole cell lysates (20 μg). Right, densitometric analysis. A blot representative of three independent experiments is shown. Data are reported as described in the legend to Figure 1B. (B) Left, C2C12 myoblasts were incubated for the indicated time intervals with or without 5 ng/ml TGFβ1 in the presence or absence of 10 μM SKI-2. Western analysis of RhoA was performed in membrane and cytosolic fractions (10 μg). Right, densitometric analysis of three independent experiments. Data are reported as described in the legend to Figure 1D. (C) Left, C2C12 myoblasts were treated with or without 5 ng/ml TGFβ1 for 8 h in the presence or in the absence of 1 μM VPC23019. Western analysis was performed as described in B. Right, densitometric analysis. Data are reported as described in the legend to Figure 1D. (D) C2C12 myoblasts, transfected with scrambled (SCR), SK1, or S1P₃ siRNA, were incubated in the presence (+) or absence (-) of 5 ng/ml TGFβ1 for 8 h. Left, Western analysis was performed as described in B. Right, densitometric analysis is reported as described in the legend to Figure 1D.

are exploited by TGFβ1 to elicit multiple biological effects. It is also interesting to note that the here identified Smad-

dependent up-regulation of SK1/S1P₃ brought about by TGFβ1 contributes to better define at mechanistic level the




Figure 10. SK1/S1P₃ pathway is implicated in the antimyogenic action of TGFβ1. Top left, C2C12 myoblasts were incubated for the indicated time-intervals with (+) or without (-) 5 ng/ml TGFβ1. The content of MHC and caveolin-3 (Cav 3) was analyzed by Western blot in aliquots (20 μg) of whole cell lysates. Top right, densitometric analysis. Data are reported as described in the legend to Figure 1B. Middle left, C2C12 myoblasts were incubated in the presence of 10 μM SKI-2, 60 min before 5 ng/ml TGFβ1 challenge for 48 h and analyzed for myogenic marker expression. Middle right, densitometric analysis. Data are reported as described in the legend to Figure 1B. Bottom left, C2C12 myoblasts, transfected with scrambled (SCR), SK1, or S1P₃ siRNA, were incubated in the presence (+) or absence (-) of 5 ng/ml TGFβ1. The content of Cav 3 was analyzed as described in A. Bottom right, densitometric analysis is reported as described in the legend to Figure 1B.

well-known antimyogenic action elicited by TGFβ1 via Smad proteins (Liu *et al.*, 2001; Zhu *et al.*, 2004).

It should be noted that our study on S1PR expression relies exclusively on expression levels of mRNA, due to the lack of suitable S1P₃ and S1P₂ antibodies. However, even though the actual increase of S1P₃ and decrease of S1P₂ protein content could not be measured, the altered S1PR profile at myoblast plasma membrane could be inferred from the finding that in myoblasts exogenous S1P is myogenic and not profibrotic, but after TGFβ1 treatment it becomes able to enhance fibrosis and reduce myogenic marker expression, similarly to what observed in S1P₃-overexpressing myoblasts.

Several lines of experimental evidence are provided here in support of a key role of S1P₃ in transmitting the profibrotic action of TGFβ1 in myoblasts. In agreement, S1P₃ was previously individuated downstream of TGFβ1 regulation of α-SMA expression in lung fibroblasts (Kono *et al.*, 2007), although in these cells it shared with S1P₂ the profibrotic signaling. Moreover, the structural analogue of S1P, FTY720-phosphate, has been recently reported to elicit myofibroblast differentiation of fibroblasts via S1P₃, because its effect was abrogated in S1P₃-null mice (Keller *et al.*, 2007). Intriguingly, in the same study Smad3 activation was identified downstream of S1P₃ signaling, whereas here Smad3, together with Smad2 and Smad4, was found upstream of S1P₃ transcriptional regulation, suggesting the occurrence of positive loop in the regulation of these two proteins worth of a more careful investigation.

The Rho/Rho kinase pathway is known to be involved in the fibrotic process that affects multiple different tissues (Dolman *et al.*, 2008; Soon and Yee, 2008; Haudek *et al.*, 2009). Interestingly, in our study Rho/Rho kinase was identified upstream of S1P₃-dependent up-regulation of fibrosis marker expression brought about by TGFβ1. These data are in agreement with a previous study in which Rho kinase was found implicated in the mechanism by which SK1 regulates differentiation of lung fibroblasts mediated by TGFβ1 (Kono *et al.*, 2007).

Another original finding of this study entails the up-regulation of S1P₄ by TGFβ1, supporting the notion that




Figure 11. Working model of the mechanism by which TGFβ1 elicits myoblast transdifferentiation into myfibroblasts.

S1P₄ in addition to acting in lymphoid tissue (Wang *et al.*, 2005; Matsuyuki *et al.*, 2006) is probably involved in biological responses in other cellular settings. The delayed enhancement of S1P₄ expression in comparison with the more rapid induction of SK1 and S1P₃ suggests that its up-regulation requires the synthesis of secondary factors downstream of TGFβ1. Although in this study S1P₄ was found disengaged from the TGFβ1-induced profibrotic response its transcriptional regulation by TGFβ1 probably participates to some other molecular event that concur to achieve the full biological response to the cytokine.

In summary, the present results for the first time demonstrate the key role of SK1/S1P₃ axis in the TGFβ1-induced transdifferentiation of myoblasts into myofibroblasts and more importantly demonstrate that TGFβ1 by remodelling S1PR expression redirects the promyogenic effect of endogenous S1P into a profibrotic, antidifferentiating cue. A model of TGFβ1 action is illustrated in Figure 11.

The concept that the peculiar flexibility of S1P inside-out signaling is strictly dependent on a given S1PR profile is also supported by a previous study in which platelet-derived growth factor-BB-induced up-regulation of SK1 and SK2, together with that of S1P₂, was found as part of a regulatory loop finalized to trigger hepatic wound repair by hepatic myofibroblasts (Serriere-Lanneau *et al.*, 2007). In the same vein, up-regulation of S1P₂ triggered by cross-linking of the high-affinity receptor for immunoglobulin E, contributed to the regulatory balance between mast cell migration and degranulation (Jolly *et al.*, 2004).

TGFβ1 is the main elicitor of overproduction of the extracellular matrix proteins that cause muscle fibrosis, a biological process that negatively interferes with repair and functional recovery of injured skeletal muscle (Best and Hunter, 2000; Sato *et al.*, 2003; Li *et al.*, 2004). Thus, neutralization of TGFβ1 action seems to be a promising approach to improve muscle regeneration (Huard *et al.*, 2002; Cohn *et al.*, 2007). Finally, it is worth mentioning that the adverse effects exerted by TGFβ1 on muscle regeneration in multiple myopathic states imply not only the stimulation of fibrotic response but also a decline of performance of satellite cells, the muscle-resident stem cells that differentiate into myoblasts (Cohn *et al.*, 2007). In this regard, because S1P has been individuated among the most powerful regulators of satellite cell proliferation (Nagata *et al.*, 2006), it seems to be of great importance to understand whether cross-talk with S1P pathway plays any role in the deleterious action of TGFβ1 in these cells.

In conclusion, this study has identified the unique ability of TGFβ1 to exploit S1P signaling to transdifferentiate myoblasts into myofibroblasts, by simultaneously affecting SK1 and S1PR expression pattern, providing new clues on the molecular mechanisms underlying the profibrotic and antidifferentiating response elicited by the cytokine that could be pharmacologically addressed to ameliorate skeletal muscle regeneration.

ACKNOWLEDGMENTS

We are indebted to Dr. Y. Banno for providing SK1 antibodies and to Dr. S. Nakamura for providing SK2 antibodies. We thank Dr. Giuditta Illuzzi for the technical assistance with digital autoradiography analysis, performed in the Radiochemistry Laboratory at the Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan. This research was supported by grants from Italian Ministry of University and Scientific Research (PRIN2007), Telethon Italy (GGP08053), University of Florence, and Ente Cassa di Risparmio di Firenze.

REFERENCES

- Alvarez, S. E., Milstien, S., and Spiegel, S. (2007). Autocrine and paracrine roles of sphingosine-1-phosphate. *Trends Endocrinol. Metab.* 18, 300–307.
- Best, T. M., and Hunter, K. D. (2000). Muscle injury and repair. *Phys. Med. Rehabil. Clin. N. Am.* 11, 251–266.
- Cohn, R. D., *et al.* (2007). Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. *Nat. Med.* 13, 204–210.
- Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 425, 577–584.
- Dolman, M. E., Fretz, M. M., Segers, G. J., Lacombe, M., Prakash, J., Storm, G., Hennink, W. E., and Kok, R. J. (2008). Renal targeting of kinase inhibitors. *Int. J. Pharm.* 364, 249–257.
- Donati, C., Cencetti, F., De Palma, C., Rapizzi, E., Brunelli, S., Cossu, G., Clementi, E., and Bruni, P. (2009). TGFbeta protects mesoangioblasts from apoptosis via sphingosine kinase-1 regulation. *Cell Signal.* 21, 228–236.
- Donati, C., Cencetti, F., Nincheri, P., Bernacchioni, C., Brunelli, S., Clementi, E., Cossu, G., and Bruni, P. (2007a). Sphingosine 1-phosphate mediates proliferation and survival of mesoangioblasts. *Stem Cells* 25, 1713–1719.
- Donati, C., Meacci, E., Nuti, F., Beccioli, L., Farnararo, M., and Bruni, P. (2005). Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor. *FASEB J.* 19, 449–451.
- Donati, C., Nincheri, P., Cencetti, F., Rapizzi, E., Farnararo, M., and Bruni, P. (2007b). Tumor necrosis factor-alpha exerts pro-myogenic action in C2C12 myoblasts via sphingosine kinase/S1P2 signaling. *FEBS Lett.* 581, 4384–4388.
- Gellings Lowe, N., Swaney, J. S., Moreno, K. M., and Sabbadini, R. A. (2009). Sphingosine-1-phosphate and sphingosine kinase are critical for TGF-[beta]-stimulated collagen production by cardiac fibroblasts. *Cardiovasc. Res.* 82, 303–312.
- Gosselin, L. E., Williams, J. E., Deering, M., Brazeau, D., Koury, S., and Martinez, D. A. (2004). Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. *Muscle Nerve* 30, 645–653.
- Haudek, S. B., Gupta, D., Dewald, O., Schwartz, R. J., Wei, L., Trial, J., and Entman, M. L. (2009). Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. *Cardiovasc. Res.* 83, 511–518.
- Hawke, T. J., and Garry, D. J. (2001). Myogenic satellite cells: physiology to molecular biology. *J. Appl. Physiol.* 91, 534–551.
- Huard, J., Li, Y., and Fu, F. H. (2002). Muscle injuries and repair: current trends in research. *J. Bone Joint Surg. Am.* 84A, 822–832.
- Igarashi, N., Okada, T., Hayashi, S., Fujita, T., Jahangeer, S., and Nakamura, S. (2003). Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. *J. Biol. Chem.* 278, 46832–46839.
- Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinosa, C., Proia, R. L., Rivera, J., Milstien, S., and Spiegel, S. (2004). Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. *J. Exp. Med.* 199, 959–970.
- Keller, C. D., Rivera, G. P., Tolle, M., van der, G. M., Chun, J., Radeke, H. H., Schafer-Korting, M., and Kleuser, B. (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. *Am. J. Pathol.* 170, 281–292.
- Kihara, A., Ikeda, M., Kariya, Y., Lee, E. Y., Lee, Y. M., and Igarashi, Y. (2003). Sphingosine-1-phosphate lyase is involved in the differentiation of F9 embryonal carcinoma cells to primitive endoderm. *J. Biol. Chem.* 278, 14578–14585.
- Kono, Y., Nishiuma, T., Nishimura, Y., Kotani, Y., Okada, T., Nakamura, S., and Yokoyama, M. (2007). Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. *Am. J. Respir. Cell Mol. Biol.* 37, 395–404.
- Leask, A., and Abraham, D. J. (2004). TGF-beta signaling and the fibrotic response. *FASEB J.* 18, 816–827.
- Li, Y., Foster, W., Deasy, B. M., Chan, Y., Prisk, V., Tang, Y., Cummins, J., and Huard, J. (2004). Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. *Am. J. Pathol.* 164, 1007–1019.
- Li, Y., and Huard, J. (2002). Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. *Am. J. Pathol.* 161, 895–907.
- Liu, D., Black, B. L., and Derynck, R. (2001). TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. *Genes Dev.* 15, 2950–2966.
- Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402–408.

- Massague, J., and Wotton, D. (2000). Transcriptional control by the TGF-beta/Smad signaling system. *EMBO J* 19, 1745–1754.
- Matsuyuki, H., Maeda, Y., Yano, K., Sugahara, K., Chiba, K., Kohno, T., and Igarashi, Y. (2006). Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. *Cell Mol. Immunol.* 3, 429–437.
- Meacci, E., Cencetti, F., Donati, C., Nuti, F., Farnararo, M., Kohno, T., Igarashi, Y., and Bruni, P. (2003). Down-regulation of EDG5/S1P2 during myogenic differentiation results in the specific uncoupling of sphingosine 1-phosphate signalling to phospholipase D. *Biochim. Biophys. Acta* 1633, 133–142.
- Meacci, E., Donati, C., Cencetti, F., Romiti, E., and Bruni, P. (2000). Permissive role of protein kinase C alpha but not protein kinase C delta in sphingosine 1-phosphate-induced Rho A activation in C2C12 myoblasts. *FEBS Lett.* 482, 97–101.
- Meacci, E., Nuti, F., Donati, C., Cencetti, F., Farnararo, M., and Bruni, P. (2008). Sphingosine kinase activity is required for myogenic differentiation of C2C12 myoblasts. *J. Cell Physiol.* 214, 210–220.
- Miller, A. V., Alvarez, S. E., Spiegel, S., and Lebman, D. A. (2008). Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. *Mol. Cell Biol.* 28, 4142–4151.
- Murate, T., *et al.* (2001). Cell type-specific localization of sphingosine kinase 1a in human tissues. *J. Histochem. Cytochem.* 49, 845–855.
- Nagata, Y., Partridge, T. A., Matsuda, R., and Zammit, P. S. (2006). Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. *J. Cell Biol.* 174, 245–253.
- Olivera, A., Rosenthal, J., and Spiegel, S. (1994). Sphingosine kinase from Swiss 3T3 fibroblasts: a convenient assay for the measurement of intracellular levels of free sphingoid bases. *Anal. Biochem.* 223, 306–312.
- Olson, E. N., Sternberg, E., Hu, J. S., Spizz, G., and Wilcox, C. (1986). Regulation of myogenic differentiation by type beta transforming growth factor. *J. Cell Biol.* 103, 1799–1805.
- Olwin, B. B., and Hall, Z. W. (1985). Developmental regulation of laminin accumulation in the extracellular matrix of a mouse muscle cell line. *Dev. Biol.* 112, 359–367.
- Prinetti, A., Chigorno, V., Tettamanti, G., and Sonnino, S. (2000). Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. *J. Biol. Chem.* 275, 11658–11665.
- Rahimi, R. A., and Leof, E. B. (2007). TGF-beta signaling: a tale of two responses. *J. Cell Biochem.* 102, 593–608.
- Sato, K., Li, Y., Foster, W., Fukushima, K., Badlani, N., Adachi, N., Usas, A., Fu, F. H., and Huard, J. (2003). Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. *Muscle Nerve* 28, 365–372.
- Serriere-Lanneau, V., *et al.* (2007). The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. *FASEB J.* 21, 2005–2013.
- Soon, R. K., Jr., and Yee, H. F., Jr. (2008). Stellate cell contraction: role, regulation, and potential therapeutic target. *Clin. Liver Dis.* 12, 791–803, viii.
- Swaney, J. S., Moreno, K. M., Gentile, A. M., Sabbadini, R. A., and Stoller, G. L. (2008). Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. *Exp. Eye Res.* 87, 367–375.
- Urata, Y., Nishimura, Y., Hirase, T., and Yokoyama, M. (2005). Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. *Kobe J. Med. Sci.* 51, 17–27.
- Wang, W., Graeler, M. H., and Goetzl, E. J. (2005). Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. *FASEB J.* 19, 1731–1733.
- Watterson, K. R., Lanning, D. A., Diegelmann, R. F., and Spiegel, S. (2007). Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. *Wound Repair Regen.* 15, 607–616.
- Woodcock-Mitchell, J., Mitchell, J. J., Low, R. B., Kieny, M., Sengel, P., Rubbia, L., Skalli, O., Jackson, B., and Gabbiani, G. (1988). Alpha-smooth muscle actin is transiently expressed in embryonic rat cardiac and skeletal muscles. *Differentiation* 39, 161–166.
- Yamanaka, M., Shegogue, D., Pei, H., Bu, S., Bielawska, A., Bielawski, J., Pettus, B., Hannun, Y. A., Obeid, L., and Trojanowska, M. (2004). Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. *J. Biol. Chem.* 279, 53994–54001.
- Zhu, S., Goldschmidt-Clermont, P. J., and Dong, C. (2004). Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. *Circ. Res.* 94, 617–625.